Drug Profile
PNQ 154
Alternative Names: PNQ-154Latest Information Update: 16 Jun 2020
Price :
$50
*
At a glance
- Originator Advinus Therapeutics
- Developer Impetis Biosciences
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diffuse large B cell lymphoma; Mantle-cell lymphoma; Rheumatoid arthritis